Lista de obras - John L. Nitiss - Dominio Público Uruguay

A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents

artículo científico publicado en 2019

A conserved SUMO pathway repairs topoisomerase DNA-protein cross-links by engaging ubiquitin-mediated proteasomal degradation

artículo científico publicado en 2020

A copper connection to the uptake of platinum anticancer drugs.

artículo científico publicado en 2002

A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II alpha

artículo científico publicado en 2003

A mutant yeast topoisomerase II (top2G437S) with differential sensitivity to anticancer drugs in the presence and absence of ATP.

artículo científico publicado en 1998

A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II

artículo científico publicado en 2004

A mutation in human topoisomerase II alpha whose expression is lethal in DNA repair-deficient yeast cells

artículo científico

A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons

artículo científico publicado en 2000

A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors

artículo científico publicado en 1993

A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine.

artículo científico publicado en 1995

Aberrant topoisomerase-1 DNA lesions are pathogenic in neurodegenerative genome instability syndromes

artículo científico publicado en 2014

Aclacinomycin A stabilizes topoisomerase I covalent complexes

scientific article published on 01 October 1997

Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase IIalpha protein levels and decreasing sensitivity to topoisomerase-targeted drugs.

artículo científico publicado en 2005

Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II ⬇️

artículo científico publicado el 15 de agosto de 1992

Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance

artículo científico publicado en 2003

Antifungal activity of eupolauridine and its action on DNA topoisomerases

artículo científico publicado en 2002

Assessing sensitivity to antibacterial topoisomerase II inhibitors

artículo científico publicado en 2007

Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha.

artículo científico publicado en 2004

Biologically active carbazole alkaloids from Murraya koenigii

artículo científico publicado en 1999

Chemical reactivity and microbicidal action of bethoxazin

artículo científico publicado en 2012

Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.

artículo científico publicado en 1998

DNA Damage by an essential enzyme: A delicate balance act on the tightrope

scientific article published on 09 July 2019

DNA repair functions that control sensitivity to topoisomerase-targeting drugs

artículo científico publicado en 2004

DNA topoisomerase II and its growing repertoire of biological functions.

artículo científico publicado en 2009

DNA topoisomerase II as a target for cancer chemotherapy.

artículo científico publicado en 2002

DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.

artículo científico publicado en 1995

DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement

artículo científico publicado en 1999

DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage

artículo científico publicado en 2002

Detection of Topoisomerase Covalent Complexes in Eukaryotic Cells

artículo científico publicado en 2018

Effects of an unusual poison identify a lifespan role for Topoisomerase 2 in Saccharomyces cerevisiae.

artículo científico publicado en 2017

End-processing during non-homologous end-joining: a role for exonuclease 1

artículo científico publicado en 2010

Enhancing drug accumulation in Saccharomyces cerevisiae by repression of pleiotropic drug resistance genes with chimeric transcription repressors

artículo científico publicado en 2008

Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents.

artículo científico publicado en 1996

Gimatecan (sigma-tau industrie farmaceutiche riunite/novartis).

artículo científico publicado en 2005

Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha.

artículo científico publicado en 2002

Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform

artículo científico publicado en 1999

Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action

artículo científico publicado en 2002

Interaction model for anthracycline activity against DNA topoisomerase II.

artículo científico publicado en 2004

Interaction of human DNA topoisomerase II alpha with DNA: quantification by surface plasmon resonance

artículo científico publicado en 2002

Investigating the biological functions of DNA topoisomerases in eukaryotic cells

article

Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks

artículo científico publicado en 2008

Kinetic Study of DNA Topoisomerases by Supercoiling-Dependent Fluorescence Quenching

artículo científico publicado en 2019

Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.

artículo científico publicado en 2001

Metabolites of daidzein and genistein and their biological activities

artículo científico publicado en 1995

Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions.

artículo científico publicado en 1999

Mutation of a conserved active site residue converts tyrosyl-DNA phosphodiesterase I into a DNA topoisomerase I-dependent poison

artículo científico publicado en 2007

Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions.

artículo científico publicado en 1999

Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.

artículo científico publicado en 1994

Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity.

artículo científico publicado en 1999

N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance

scientific article published on 01 September 2000

Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha

artículo científico publicado en 2003

Proteolytic Degradation of Topoisomerase II (Top2) Enables the Processing of Top2⋅DNA and Top2⋅RNA Covalent Complexes by Tyrosyl-DNA-Phosphodiesterase 2 (TDP2)

artículo científico publicado en 2014

Repair of topoisomerase I-mediated DNA damage

artículo científico publicado en 2006

Roles of DNA topoisomerases in chromosomal replication and segregation.

artículo científico publicado en 1994

Roles of eukaryotic topoisomerases in transcription, replication and genomic stability

artículo científico publicado en 2016

Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage

scientific article published on 01 June 2006

Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis

artículo científico publicado en 2005

TDP1 is required for efficient non-homologous end joining in human cells.

artículo científico publicado en 2017

TDP1 promotes assembly of non-homologous end joining protein complexes on DNA.

artículo científico publicado en 2015

Targeting DNA topoisomerase II in cancer chemotherapy

artículo científico publicado en 2009

Tdp2: A Means to Fixing the Ends ⬇️

artículo científico publicado el 7 de marzo de 2013

The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.

artículo científico publicado en 2012

The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II.

artículo científico publicado en 1998

The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine

artículo científico publicado en 1993

Thioguanine substitution alters DNA cleavage mediated by topoisomerase II

artículo científico publicado en 2000

Topoisomerase Assays ⬇️

artículo científico publicado el 1 de mayo de 2001

Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine.

artículo científico publicado en 2001

Topoisomerase assays

artículo científico publicado en 2012

Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast

artículo científico publicado en 2020

Twisting and ironing: doxorubicin cardiotoxicity by mitochondrial DNA damage

artículo científico publicado en 2014

Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage

artículo científico publicado en 2006

UnTTrapping the ends: a new player in overcoming protein linked DNA damage

artículo científico publicado en 2010

Using yeast to study resistance to topoisomerase II-targeting drugs.

artículo científico publicado en 1994

Using yeast to understand drugs that target topoisomerases.

artículo científico publicado en 1996

Yeast Tdp1 regulates the fidelity of nonhomologous end joining

artículo científico publicado en 2010

Yeast as a genetic model system for studying topoisomerase inhibitors.

artículo científico publicado en 1994

Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks

artículo científico publicado en 2003

Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.

artículo científico publicado en 1994

Lista de obras de John L. Nitiss

A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents

A conserved SUMO pathway repairs topoisomerase DNA-protein cross-links by engaging ubiquitin-mediated proteasomal degradation

A copper connection to the uptake of platinum anticancer drugs.

A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II alpha

A mutant yeast topoisomerase II (top2G437S) with differential sensitivity to anticancer drugs in the presence and absence of ATP.

A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II

A mutation in human topoisomerase II alpha whose expression is lethal in DNA repair-deficient yeast cells

A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons

A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors

A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine.

Aberrant topoisomerase-1 DNA lesions are pathogenic in neurodegenerative genome instability syndromes

Aclacinomycin A stabilizes topoisomerase I covalent complexes

Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase IIalpha protein levels and decreasing sensitivity to topoisomerase-targeted drugs.

Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II ⬇️

Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance

Antifungal activity of eupolauridine and its action on DNA topoisomerases

Assessing sensitivity to antibacterial topoisomerase II inhibitors

Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha.

Biologically active carbazole alkaloids from Murraya koenigii

Chemical reactivity and microbicidal action of bethoxazin

Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.

DNA Damage by an essential enzyme: A delicate balance act on the tightrope

DNA repair functions that control sensitivity to topoisomerase-targeting drugs

DNA topoisomerase II and its growing repertoire of biological functions.

DNA topoisomerase II as a target for cancer chemotherapy.

DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.

DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement

DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage

Detection of Topoisomerase Covalent Complexes in Eukaryotic Cells

Effects of an unusual poison identify a lifespan role for Topoisomerase 2 in Saccharomyces cerevisiae.

End-processing during non-homologous end-joining: a role for exonuclease 1

Enhancing drug accumulation in Saccharomyces cerevisiae by repression of pleiotropic drug resistance genes with chimeric transcription repressors

Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents.

Gimatecan (sigma-tau industrie farmaceutiche riunite/novartis).

Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha.

Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform

Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action

Interaction model for anthracycline activity against DNA topoisomerase II.

Interaction of human DNA topoisomerase II alpha with DNA: quantification by surface plasmon resonance

Investigating the biological functions of DNA topoisomerases in eukaryotic cells

Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks

Kinetic Study of DNA Topoisomerases by Supercoiling-Dependent Fluorescence Quenching

Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.

Metabolites of daidzein and genistein and their biological activities

Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions.

Mutation of a conserved active site residue converts tyrosyl-DNA phosphodiesterase I into a DNA topoisomerase I-dependent poison

Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions.

Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.

Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity.

N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance

Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha

Proteolytic Degradation of Topoisomerase II (Top2) Enables the Processing of Top2⋅DNA and Top2⋅RNA Covalent Complexes by Tyrosyl-DNA-Phosphodiesterase 2 (TDP2)

Repair of topoisomerase I-mediated DNA damage

Roles of DNA topoisomerases in chromosomal replication and segregation.

Roles of eukaryotic topoisomerases in transcription, replication and genomic stability

Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage

Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis

TDP1 is required for efficient non-homologous end joining in human cells.

TDP1 promotes assembly of non-homologous end joining protein complexes on DNA.

Targeting DNA topoisomerase II in cancer chemotherapy

Tdp2: A Means to Fixing the Ends ⬇️

The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.

The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II.

The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine

Thioguanine substitution alters DNA cleavage mediated by topoisomerase II

Topoisomerase Assays ⬇️

Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine.

Topoisomerase assays

Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast

Twisting and ironing: doxorubicin cardiotoxicity by mitochondrial DNA damage

Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage

UnTTrapping the ends: a new player in overcoming protein linked DNA damage

Using yeast to study resistance to topoisomerase II-targeting drugs.

Using yeast to understand drugs that target topoisomerases.

Yeast Tdp1 regulates the fidelity of nonhomologous end joining

Yeast as a genetic model system for studying topoisomerase inhibitors.

Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks

Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.